Shares of Knight Therapeutics Inc. (OTCMKTS:KHTRF – Get Free Report) shot up 0.6% on Monday. The stock traded as high as $7.22 and last traded at $7.22. 1,700 shares changed hands during trading, a decline of 78% from the average daily volume of 7,792 shares. The stock had previously closed at $7.18.
Wall Street Analysts Forecast Growth
Separately, Royal Bank Of Canada reissued an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, August 7th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy”.
Check Out Our Latest Research Report on KHTRF
Knight Therapeutics Stock Performance
About Knight Therapeutics
Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative medicines. The company concentrates on therapies that address unmet medical needs, including specialty, orphan and hospital-based treatments.
Through licensing and commercialization agreements, Knight offers a portfolio of prescription products across therapeutic areas such as oncology, rare diseases, infectious diseases and neurology.
Featured Articles
- Five stocks we like better than Knight Therapeutics
- Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
- Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
- 4 Stocks That Could Split Next—and Why Investors Are Watching
- Oura’s IPO Freeze Isn’t the Warning Sign It Looks Like
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
